4559.T Stock - Zeria Pharmaceutical Co., Ltd.
Unlock GoAI Insights for 4559.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $87.31B | $75.73B | $68.38B | $59.53B | $52.76B |
| Gross Profit | $63.96B | $50.18B | $49.49B | $42.15B | $36.96B |
| Gross Margin | 73.3% | 66.3% | 72.4% | 70.8% | 70.1% |
| Operating Income | $12.20B | $9.72B | $9.01B | $6.37B | $3.48B |
| Net Income | $9.94B | $7.73B | $6.20B | $3.96B | $3.14B |
| Net Margin | 11.4% | 10.2% | 9.1% | 6.7% | 6.0% |
| EPS | $225.42 | $175.39 | $140.26 | $87.76 | $68.22 |
Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents in Japan and internationally. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; sclerosing agent for varicose veins; anti-inflammatory topical blood circulation enhancers; non-steroidal anti-inflammatory ophthalmic solutions; absorbable topical hemostat products; and proton pump inhibitors. In addition, it offers consumer healthcare products, such as nutritional health drugs, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, and food for specified health uses. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.
Visit WebsiteEarnings History & Surprises
4559.TEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 5, 2025 | — | $14.68 | — | — |
Q3 2025 | Aug 5, 2025 | — | $24.75 | — | — |
Q2 2025 | May 8, 2025 | — | $38.78 | — | — |
Q1 2025 | Feb 5, 2025 | — | $49.13 | — | — |
Q4 2024 | Nov 6, 2024 | — | $41.94 | — | — |
Q3 2024 | Aug 1, 2024 | — | $95.57 | — | — |
Q2 2024 | May 9, 2024 | — | $-15.70 | — | — |
Q1 2024 | Feb 1, 2024 | — | $68.66 | — | — |
Q4 2023 | Nov 1, 2023 | — | $56.29 | — | — |
Q3 2023 | Aug 3, 2023 | — | $66.14 | — | — |
Q2 2023 | May 11, 2023 | — | $4.88 | — | — |
Q1 2023 | Feb 2, 2023 | — | $44.90 | — | — |
Q4 2022 | Nov 2, 2022 | — | $31.65 | — | — |
Q3 2022 | Aug 4, 2022 | — | $58.71 | — | — |
Q2 2022 | May 11, 2022 | — | $-1.84 | — | — |
Q1 2022 | Feb 2, 2022 | — | $42.76 | — | — |
Q4 2021 | Nov 4, 2021 | — | $15.74 | — | — |
Q3 2021 | Aug 5, 2021 | — | $30.91 | — | — |
Q2 2021 | May 11, 2021 | — | $-12.38 | — | — |
Q1 2021 | Feb 5, 2021 | — | $49.83 | — | — |
Latest News
Frequently Asked Questions about 4559.T
What is 4559.T's current stock price?
What is the analyst price target for 4559.T?
What sector is Zeria Pharmaceutical Co., Ltd. in?
What is 4559.T's market cap?
Does 4559.T pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to 4559.T for comparison